The world’s first potential therapy for an increasingly common, chronic lung condition has been identified following a trial ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

This finding not only provides a new treatment option for patients with bronchiectasis but also lays a solid foundation for the development of more targeted therapies in the future. This study ...

19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of brensocatib, administered once daily for 24 weeks, prolonged the time to the first ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis ...

Bronchodilators have a limited role in bronchiectasis management compared ... making antibiotics a mainstay of treatment. Augmented mucus clearance is a crucial complementary approach.

Treatment with brensocatib also increased ... brensocatib could become the first approved treatment for patients with bronchiectasis as well as the first DPP-1 inhibitor. Brensocatib works on ...

Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically ... exacerbations versus placebo over the 52-week treatment period. The annualized rate of exacerbations ...